Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Teleflex

Evaluate

Thumbnail
January 06, 2022

A bad year to be an American medtech

Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.

Thumbnail
October 30, 2020

Teleflex recommits to takeovers

In a time of unpredictable demand for its products, the diversified medtech is unafraid to acquire.

Article image
Vantage logo
September 03, 2020

Medtechs that book the most sales per employee face the greatest losses

Welcome to the calm before the Covid-19 storm.

Article image
Vantage logo
February 21, 2020

Conductor deal sets the tempo for Teleflex

Article image
Vantage logo
January 09, 2018

2017 saw the stars Align for big-cap medtech

Toothy grins all round at Align, but it is unclear how much longer it can keep up its scorching rate of sales growth.

Vantage logo
October 19, 2017

Interview – Serial acquirer Teleflex seeks deals both big and small

Vantage logo
September 08, 2017

Snippet Roundup: PI3Ks not dead, but PD(L)-1 multiple myeloma hopes falter

Article image
Vantage logo
July 10, 2017

Medtech mergers surge again

Either buyers are being pickier or the pool of targets is dwindling.

Vantage logo
December 05, 2016

Teleflex-Vascular takes 2016’s medtech merger total to $73bn

Vantage logo
July 06, 2016

Smaller medtechs in charge of their own destiny

Vantage logo
October 29, 2012

2012 sees largest pure medtech buy for seven years, but value of deals slump 27%

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up